Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Rimiducid

Catalog No: tcsc3162

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
195514-63-7

Formula:
$C_{78}H_{98}N_4O_{20}$

Pathway:
Apoptosis

Target:
TNF Receptor

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 54 mg/mL (38.25 mM)

Alternative Names:
AP1903

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
1411.63

Product Description

Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the **FKBP** domains, initiating **Fas** signaling and hence **apoptosis**.

IC50 & Target: EC50: 0.1 nM (FKBP, in HT1080 cells)[1]

Fas receptor[1]

In Vitro: The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC_{50} of ≈0.1 nM[1]. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC_{50} is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment[2].

In Vivo: Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum hGH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg[1].